MedPath

Efficacy of Ketofol (drug) for critically ill patients with liverdisease.

Phase 2
Conditions
Health Condition 1: K721- Chronic hepatic failure
Registration Number
CTRI/2024/04/066049
Lead Sponsor
Institute of Liver and Biliary Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Age 18years or more

2.Advanced liver disease with MELDNa 15 or more

3.Undergoing elective endotracheal intubation

Exclusion Criteria

1.

2.Refusal to consent

3.Allergic to any of the agents being used

4.Pregnancy

5.Patients needing CPR

6.Patients with anticipated difficult airway

7.Acute liver failure

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
- To compare the incidence of post intubation hypotension occurring within 6 hours of intubation <br/ ><br>between etomidate and ketofol use for sedation during endotracheal intubations in liver ICUTimepoint: Within 6 hours
Secondary Outcome Measures
NameTimeMethod
7-day mortalityTimepoint: first 7 days post intubation;Fall /Change in MAP from baseline for 1st 6 hours after intubationTimepoint: Within 6 hours post intubation;Incidence of post intubation hypertension within 6 hours of intubationTimepoint: Within 6 hours post intubation;Intubation difficulty scoreTimepoint: Day 0;Length of ICU stayTimepoint: 7 days;Number of days on ventilatorTimepoint: 7 days;Number of patients requiring vasopressors within 24 hrs of intubationTimepoint: within 24 hours post intubation;SOFA score at 1 hr and 24 hours post intubationTimepoint: 1 hr and 24 hrs after intubation;Total and peak dose of vasopressor requirement within 24 hrs post intubationTimepoint: within 24 hours of intubation
© Copyright 2025. All Rights Reserved by MedPath